Tenderwize
Retour à la recherche

Open house Arzneimittelrabattverträge Tofacitinib, ATC L04AF01

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jun 03, 2027 · 277 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tofacitinib, ATC L04AF01

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

The open house model is not subject to procurement law; limited legal remedies. Disputes handled by social courts, not...

Failure to follow correct submission method (physical vs. electronic) or missing documents may delay or prevent contrac...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Supply of pharmaceutical products containing Tofacitinib (ATC L04AF01) under non-exclusive discount agreements.
  • Contracts are standardized and not individually negotiable.
Afficher le résumé complet

Open house model for non-exclusive discount agreements (Rabattverträge) on Tofacitinib (ATC L04AF01) by AOK Bayern. Pharmaceutical companies can join at any time until 03.06.2027. Contracts run from 01.08.2025 to 31.07.2027. The procedure is not subject to procurement law; no selection or competition among tenderers.

Risques

The open house model is not subject to procurement law; limited legal remedies. Disputes handled by social courts, not...

Failure to follow correct submission method (physical vs. electronic) or missing documents may delay or prevent contrac...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible.

Administrative

  • Submit signed contract, signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed self-declaration of reliability.
  • Submission either in physical form (2 copies) with handwritten signature or electronically with qualified electronic signature.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria – open house model, no selection.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house Arzneimittelrabattverträge Tofacitinib, ATC L04AF01

Open house for non-exclusive discount agreements on Tofacitinib. All eligible pharmaceutical companies may join. Contracts are identical and not individually negotiable. Performance location: Bavaria, Germany.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Jul 2025 - Jul 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria – open house model, no selection.

Date limite

Deadline Jun 03, 2027

Détails de la procédure

Date de publication
15 Jun 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
387344-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30